Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H8YL | ISIN: US45257L1089 | Ticker-Symbol: YP1A
Tradegate
25.06.25 | 17:02
1,330 Euro
-5,67 % -0,080
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
IMMUTEP LIMITED ADR Chart 1 Jahr
5-Tage-Chart
IMMUTEP LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,3101,51007:00
1,3901,42027.06.

Aktuelle News zur IMMUTEP LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SoImmutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data6
IMMUTEP LIMITED ADR Aktie jetzt für 0€ handeln
DiIMMUTEP Ltd - 6-K, Report of foreign issuer11
23.06.Immutep Limited: Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases757Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction...
► Artikel lesen
22.06.IMMUTEP LIMITED: Update on Phase I Study of IMP761 for Autoimmune Diseases1
27.05.Immutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma312Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned...
► Artikel lesen
26.05.Immutep's efti combination meets primary endpoint in Phase II soft tissue sarcoma trial7
26.05.Primary goal achieved: Immutep reports strong Phase II results in sarcoma trial7
16.05.Hot Stocks: Peak Rare Earths, Amplia, Immutep, Webjet, Aristocrat Leisure5
15.05.Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo4
15.05.Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial13
15.05.Health Check: Amplia shares surge on pancreatic cancer trial results; Immutep offers hope9
15.05.Hot Stocks: Immutep, Xero, GrainCorp15
15.05.Immutep lung cancer trial delivers strong response rates, even in hardest-to-treat patients3
09.05.Hot Stocks: NAB, Macquarie, Immutep, Chrysos3
05.05.Immutep-Aktie steigt nach vielversprechenden Studienergebnissen21
05.05.Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo7
05.05.Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial9
05.05.Immutep posts strong survival results for head and neck cancer patients9
05.05.Hot Stocks: Westpac, Tyro, Immutep, Syrah, Turaco7
29.04.Immutep Limited: Immutep Quarterly Activities Report Q3 FY25218Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC)...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1